SOLO-Symbicort® in the Treatment of Persistent Asthma in Adolescents & Adults

AstraZeneca

Status and phase: Completed; Phase 3

Conditions: Asthma

Treatments: Drug: Budesonide/formoterol Turbuhaler

Study type: Interventional

Funder types: Industry

Identifiers

NCT00238784

SOLO

D5890L00004

Details and patient eligibility

About

The purpose of this study is to compare Symbicort Single Inhaler treatment with the Best Conventional Practice in patients with persistent asthma

Sex: All

Ages: 12+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of asthma < 3 months
• Prescribed daily use of glucocorticosteroids for at least 3 months prior to Visit 1

Exclusion criteria

• Smoking history > 10 pack-years
• Asthma exacerbation requiring change in asthma treatment during the last 14 days prior to inclusion
• Any significant disease or disorder that my jeopardize the safety of the patient.

Additional inclusion and exclusion criteria will be evaluated by the investigator.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)